Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy
Article Abstract:
HIV can become resistant to more than one drug when patients are treated with multiple drugs. This was the conclusion of a study of 64 patients taking zidovudine or lamivudine or both. Zidovudine resistance was less frequent in those who took both drugs, but several patients eventually became resistant to both drugs.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation
Article Abstract:
The antiretroviral (ARV) treatment decisions for HIV-1-infected patients on complex treatment regimens who have partial suppression of HIV-1 replication and limited treatment options are studied. Nucleoside analogue reverse transcriptase inhibitors may have continued ARV activity despite long durations of partially suppressive therapy and the presence of resistant HIV-1.
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter
Article Abstract:
Lamivudine and zidovudine together may be more effective than either drug alone in increasing CD4+ levels and reducing indicators of the level of virus in the blood. A total of 366 HIV-infected people received either 200 milligrams (mg)/8 hours (hr) of zidovudine alone; 300 mg/12 hr of lamivudine alone; 150 mg/12 hr of lamivudine plus 200 mg/8 hr of zidovudine; or 300 mg/12 hr of lamivudine plus 200 mg/8 hr of zidovudine. Patients received treatment for 24 weeks and were followed for a total of 52 weeks. At 24 and 52 weeks, CD4+ counts increased by more among each combination group than among the individual drug groups. Levels of HIV-1 RNA in blood plasma dropped more among the combination groups than among the individual drug groups. Side effects occurred more among people receiving zidovudine. These effects included increased liver activity, nausea, headache, numbness, and anemia.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients
- Abstracts: Histologic and biochemical study of the brain, heart, kidney, and liver in asphyxia caused by occlusion of the umbilical cord in near-term fetal lambs
- Abstracts: Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: a randomized trial of double versus triple therapy